Abstract 10P
Background
As a result of a significant decrease in smoking prevalence in many countries, the overall incidence of head and neck squamous cell carcinoma (HNSCC) is declining. However, there is a growing recognition of an increased incidence of oral tongue squamous cell carcinoma (OTSCC) in non-smokers and non-drinkers (NSND) for reasons that are yet to be fully understood. OTSCC in NSND and smoker-drinker (SD) individuals have different molecular profiles, as well as distinct immune microenvironments, which may affect their susceptibility to targeted therapies and immunotherapy. The prognostic value of tumor-infiltrating lymphocytes (TILs) and tertiary lymphoid structures (TLS) in localized oral tongue squamous cell carcinoma (OTSCC) remains unclear. This study investigates the prognostic impact of TILs and TLS on recurrence in patients with surgically treated OTSCC in NSND.
Methods
A total of 100 patients with OTSCC underwent complete surgical resection at a single institution with a median follow-up of 35 months (IQR 12-60). TIL presence (minimal, moderate, heavy) and TLS maturation (aggregate, primary follicle, secondary follicle) were graded using brightfield H&E slides according to previously published criteria. The prognostic impact of TILs and TLS on survival was analyzed using multivariable Cox regression, adjusting for prognostic factors (tumor size, depth of invasion, grade, and surgical margin status). Multivariable logistic regression was used to evaluate these factors for associations with early recurrence (≤12 months).
Results
Heavy TIL presence was observed in 41% of cases, and TLS was present in 76%, of which 23% were mature. The presence of mature TLS was associated with reduced odds of early recurrence [OR 0.18, P=0.04], and the presence of heavy TILs was associated with improved overall survival (OS) [HR 0.26, P=0.02]. Tumors categorized as TIL-/TLS- were associated with significantly worse OS [HR 3.5, P=0.02] compared to tumors with heavy TILs or mature TLS.
Conclusions
TILs and mature TLS are independently associated with decreased rate of early recurrence for high-risk localized OTSCC. Further studies should validate these potential low-cost biomarkers.
Editorial acknowledgement
During the preparation of this work the author(s) used Chat GPT in order to checking grammar. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract